This trial is active, not recruiting.

Condition pancreatic cancer
Sponsor University of Oklahoma
Start date October 2010
End date July 2015
Trial size 60 participants
Trial identifier NCT01580241, 2606


The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Patients with pancreatic cancer who undergo surgical treatment only
Patients with pancreatic cancer who undergo chemotherapy treatment only
Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
Patients with pancreatic cancer who undergo surgery followed by chemotherapy

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - pancreatic cancer Exclusion Criteria: - age < 18, history of other types of cancer

Additional Information

Official title Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma
Principal investigator Courtney Houchen, MD
Trial information was received from ClinicalTrials.gov and was last updated in December 2014.
Information provided to ClinicalTrials.gov by University of Oklahoma.